CLINICAL_TRIALS trial_result · 2023-01-31

Clinical Trial Update: A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB Patients [Phase 1, Phase 2]

Phase I/II study of KB103 (Topical HSV1-COL7) in patients with Dystrophic Epidermolysis Bullosa has completed and results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Krystal Biotech, Inc. | Conditions: Dystrophic Epidermolysis Bullosa | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-01-31